Last reviewed · How we verify
AXER-204
At a glance
| Generic name | AXER-204 |
|---|---|
| Also known as | human NoGo Trap, human Nogo Receptor decoy |
| Sponsor | ReNetX Bio, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- AXER-204 in Participants With Chronic Spinal Cord Injury (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AXER-204 CI brief — competitive landscape report
- AXER-204 updates RSS · CI watch RSS
- ReNetX Bio, Inc. portfolio CI